Quest Diagnostics 'Clinical Trials' biorepository gets CAP accreditation Quest Diagnostics announced that the specimen biorepository of its Quest Diagnostics Clinical Trials business has been accredited by the College of American Pathologists, CAP) the international laboratory accrediting organization.
News For DGX From The Last 14 Days
Check below for free stories on DGX the last two weeks.
Life Sciences highlights this week at Canaccord Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.